Global interest in viral-based oncology is currently anchored by a robust pipeline of candidates, including Cretostimogene grenadenorepvec, CAN-2409, and RP1. These treatments are designed to selectively infect cancer cells, triggering localized destruction while stimulating a systemic anti-tumor immune response. According to DelveInsight, the United States remains the primary market for these immunotherapies, which are increasingly targeting hard-to-treat conditions like pancreatic, bladder, and non-small cell lung cancer.
In section Releases
Oncolytic Virus Sector Poised for Growth Through 2036
The market for oncolytic virus cancer therapies is entering a period of accelerated expansion as pharmaceutical developers leverage genetic engineering to transform how the immune system identifies and destroys malignant tumors. With the sector valued at $177 million in 2025, clinical momentum is shifting toward therapies that convert 'cold' tumors into immunoreactive targets.
Industry leaders such as CG Oncology, Replimune, and Genelux are driving this transition through advanced clinical trials. The therapeutic potential is significant, as these viruses are being developed for relapsed or refractory settings, potentially addressing up to 20% of all cancer cases. Regulatory progress has already been established by early approvals like IMLYGIC and DELYTACT, setting a precedent for the next generation of candidates currently advancing through Phase III trials.
Comments (0)
No comments yet. Be the first!